Abstract: Sleep apnea-hypopnea syndrome (SAHS) seriously affects human sleep, so it is necessary to find the disease as early as possible. However, most of traditional models use convolutional neural ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Cytokinetics Inc. CYTK shares are up on Tuesday as the company announced positive topline results from its pivotal Phase 3 ACACIA-HCM trial, which met both dual primary endpoints. The trial evaluated ...

In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.

Introduction Identifying acute hypercapnic respiratory failure is crucial in the initial management of acute exacerbations of COPD. Guidelines recommend obtaining arterial blood samples but these are ...

Objective: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected ...

生物制药公司Cytokinetics于5月13日宣布，其3期临床试验MAPLE-HCM已达到主要终点，结果显示，与标准β受体阻滞剂美托洛尔相比，Aficamten显著改善了梗阻性肥厚型心肌病(HCM)患者的峰值摄氧量(pVO2)。 这项随机、双盲、活性对照MAPLE-HCM试验(ClinicalTrials.gov注册号 ...

I'm Jason Zemansky. I'm one of the SMID-cap analysts here at BofA, and thank you for joining us on this -- our first day, second half of our Healthcare Conference in [ Veeva ], Las Vegas. I hope it's ...

All right, everybody. We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech. And I'm pleased to ...

研究结果表明，HRS-1893可快速且持续降低关键心脏生物标志物，并改善心脏舒张功能和心脏结构指标，整体安全性和耐受性良好 研究结果为HRS-1893作为非梗阻性肥厚型心肌病的潜在治疗手段提供了证据 相关数据已在2026年欧洲心脏病学会心力衰竭协会年会 ...